I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

2024 GI Cancers Symposium

-
Coming soon
07:45 PM
Duration 90mins San Francisco, USA
MORPHEUS-EC: a phase Ib/II open-label, randomized study of tiragolumab plus atezolizumab plus chemotherapy in patients with previously untreated locally advanced unresectable or metastatic esophageal cancer
Dr Jong-Mu Sun

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:15 PM
Duration 10mins Level 3, Ballroom, Moscone Center, San Francisco
SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line tiragolumab + atezolizumab and chemotherapy in patients with esophageal squamous cell carcinoma (ESCC)
Dr Chih-Hung Hsu

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:30 PM
Duration 10mins Level 3, Ballroom, Moscone Center, San Francisco
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Results From a Randomized Proof-of-Concept Phase II Trial (IMbrave151)
Anthony B. El-Khoueiry, Zhenggang Ren, Hong Jae Chon, Joon Oh Park, Jin Won Kim, Tiziana Pressiani, Daneng Li, Lyudmila Zhukova, Andrew X. Zhu, Ming-Huang Chen, Stephen P. Hack, Stephanie Wu, Bo Liu, Xiangnan Guan, Shan Lu, Yulei Wang, Teresa Macarulla

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:30 PM
Duration 90mins San Francisco, USA
Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network
Cosgrove, David; Tan, Amie; Osterland, Andrew; Hernandez, Sairy; Ogale, Sarika; Mahrus, Sami; Murphy, John; Wilson, Thomas; Patton, Gregory; Loaiza-Bonilla, Arturo; Singal, Amit

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins San Francisco, USA
Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC)
Kaplan, David E; Tan, Amie; Xiang, Cheryl; Mu, Fan; Hernandez, Sairy; Ogale, Sarika; Sundar, Manasvi; Lin, Yilu; Shi, Lizheng; Singal, Amit G.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins San Francisco, USA
Comparing first-line (1L) atezolizumab plus bevacizumab (A+B) to lenvatinib (L) or sorafenib (S) in patients with unresectable hepatocellular carcinoma (uHCC): Findings from the National Veteran Health Administration (VHA) database
Kaplan, David E; Tan, Amie; Xiang, Cheryl; Mu, Fan; Hernandez, Sairy; Ogale, Sarika; Sundar, Manasvi; Lin, Yilu; Shi, Lizheng; Singal, Amit G.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar